China National Pharmaceutical Group Co., Ltd. releases the 2025 Performance Evaluation Report of Tianjian Certified Public Accountants

Log in to the Sina Finance app and search for 【Information Disclosure】 to view the evaluation grades

Zhongfang Network Data Sinopharm Group Consistent Pharmaceutical Co., Ltd. recently released an assessment report on Tianjian Certified Public Accountants (Special General Partnership)’s performance in carrying out its duties as the audit firm for the 2025 fiscal year. The report shows that the company believes Tianjian was compliant and effective, diligent and conscientious in its 2025 audit work, maintaining independence and fairly expressing its audit opinions.

The assessment report details Tianjian’s qualification requirements, including its organizational form as a special general partnership, its large practice team (250 partners at the end of 2025, and 2,363 registered certified public accountants), and its operating revenue of 2.97B yuan in 2024, of which revenue from the securities business reached 1.47B yuan. Tianjian has accrued sufficient professional risk funds and purchased professional liability insurance, demonstrating strong investor protection capabilities. The report also mentions that in the past three years, Tianjian has been involved in civil lawsuits arising from its practice conduct and has borne the corresponding civil liabilities; however, the relevant cases have been concluded and have not affected its ability to perform its duties.

In terms of practice records, the 2025 annual report audit projects were handled by partner Deng Huaming, the signed registered certified public accountant Zeng Xiangsheng, and the quality review personnel Ye Xianbin. This team has had no adverse practice records over the past three years. Tianjian, during project execution, has established a comprehensive quality management system, including project consultation, dispute resolution, multi-tier quality reviews, and monitoring mechanisms, to ensure the quality of audit work.

The company’s assessment concludes that Tianjian developed a comprehensive and feasible audit plan tailored to the company’s actual circumstances, equipped it with an experienced dedicated team, and completed on time the audits of the 2025 financial statements, the internal control audit, and assurance work on related-party fund occupation, effectively meeting the company’s information disclosure requirements. Ultimately, the board of directors of Sinopharm Consistent confirmed that Tianjian demonstrated good professional conduct and professional competence in its audit work for 2025, and that its performance in carrying out its duties meets the company’s requirements.

Massive amounts of information and precise interpretation—right on the Sina Finance app